MCL1 protein inhibitor - Pipeline Insight, 2024

MCL1 protein inhibitor - Pipeline Insight, 2024

DelveInsight’s, “MCL1 protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in MCL1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

MCL1 protein inhibitors Understanding

MCL1 protein inhibitors: Overview

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. MCL-1 inhibitors rapidly induce apoptosis in AML cells in a BAK dependent manner. This established activity profile together with its role in drug resistance makes it an attractive target for combination therapy approaches. Overexpression of MCL-1 is frequently observed in many other tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The central role of MCL-1 in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Significant progress has been made with regard to MCL-1 inhibitors, some of which have entered clinical trials.

""MCL1 protein inhibitors - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the MCL1 protein inhibitors pipeline landscape is provided which includes the disease overview and MCL1 protein inhibitors treatment guidelines. The assessment part of the report embraces, in depth MCL1 protein inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, MCL1 protein inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence MCL1 protein inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve MCL1 protein inhibitors.

MCL1 protein inhibitors Emerging Drugs Chapters

This segment of the MCL1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MCL1 protein inhibitors Emerging Drugs

• S64315: Servier/ Novartis

Servier is collaborating with Novartis for the clinical development of S64315. S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1 with Ki value of 1.2 nM and has potential pro-apoptotic and antineoplastic activities. The drug is currently being evaluated in Phase I/II stage of development for the treatment of Acute Myeloid Leukaemia.

• PRT1419: Prelude Therapeutics

Prelude is developing PRT1419, which is designed to be an orally available, potent, and selective inhibitor of MCL1. An oral formulation of PRT1419 is being evaluated in a Phase 1 trial in high-risk myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. An intravenous formulation will be evaluated in a Phase I trial in patients with solid tumors.

Further product details are provided in the report……..

MCL1 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different MCL1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in MCL1 protein inhibitors

There are approx. 7+ key companies which are developing the therapies for MCL1 protein inhibitors. The companies which have their MCL1 protein inhibitors drug candidates in the most advanced stage, i.e. phase I/II include Servier/ Novartis.

● Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

MCL1 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

MCL1 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses MCL1 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MCL1 protein inhibitors drugs.

MCL1 protein inhibitors Report Insights

• MCL1 protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

MCL1 protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing MCL1 protein inhibitors drugs?
• How many MCL1 protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MCL1 protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MCL1 protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for MCL1 protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?